Business Standard

Sebi censures Astrazeneca promoter, Elliot Group for unfair trade practices

Sebi said that the entire procedure was intended to dilute the reverse book building mechanism for discovery of delisting price of the scrip as per stipulations

Sebi
Premium

Stock exchanges, BSE and NSE, have been directed to closely monitor the entire delisting process to be initiated by the company in future

Agencies Mumbai
Markets regulator Sebi has "censured" Astrazeneca Pharma India Ltd's promoter and Elliot Group for professional misconduct and following unfair trade practises during the company's delisting plan in 2014.

The regulator, in a 65-page order, said that Astrazeneca Pharma India Ltd's (AZPIL) promoter AstraZeneca Pharmaceuticals AB Sweden (AZPAB), and Elliott Group, which held 15.52 per cent stake in the company, had a 'private arrangement' to sail through the delisting process, news agency PTI reported.

Sebi said it "strongly censure the noticees (AZPAB and Elliott Group) for displaying such gross professional misconduct and fraudulent trade practice and trying to arrive at a

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in